ImmunoGen Appoints David Johnston As CFO - Quick Facts

(RTTNews) - ImmunoGen, Inc. (IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate technology, has named David Johnston as Executive Vice President and Chief Financial Officer, effective today, who would report to the company's President and Chief Executive, Daniel Junius. He brings to ImmunoGen over 30 years of experience in corporate finance, including 15 years in senior financial functions at biotechnology companies, and extensive experience in corporate planning.

Johnston joins ImmunoGen from AVEO Pharmaceuticals Inc., where he was the Chief Financial Officer. Earlier to joining AVEO in 2007, he was Senior Vice President of Finance, Corporate Planning and Analysis at Genzyme Corp. and, before that, the VP Finance and CFO of Genzyme Biosurgery.